DRL’s tablets are available in 60 mg in bottle count sizes of 30, 100 and 1,000
Dr Reddy’s Laboratories has launched of Raloxifene hydrochloride tablets in 60 mg, a therapeutic equivalent generic version of Evista (raloxifene hydrochloride) tablets in the United States market, approved by the US Food & Drug Administration (US FDA).
The Evista brand and generic had US sales of approximately $265 million MAT for the most recent twelve months ending in September 2016 according to IMS Health*
Dr Reddy’s Raloxifene tablets are available in 60 mg in bottle count sizes of 30, 100 and 1,000.
EP News Bureau